CSPG4 and breast carcinoma: Moreover, the binding potential of the antibody component of αCSPG4(scFv)-SNAP was further validated by staining FFPE breast cancer tissue sections of 5 South African patients (diagnosed with TNBC) and deriving the pooled mean fluorescence intensities of CSPG4 expression from the images generated and comparing these values against non-tumor tissue sections from the same patient (Fig. 5).